Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5508376 | 0.99 | KDM4C (0.44) | KDM4CGPBAR1MCL1PIP4K2ALIMK1 | |
| SCHEMBL3903670 | 0.91 | GPBAR1 (0.47) | KDM4CGPBAR1MCL1PIP4K2A | |
| SCHEMBL2000076 | 0.85 | GSK3B (0.44) | KDM4CGPBAR1PIP4K2A | |
| SCHEMBL3150902 | 0.85 | LIMK1 (0.48) | KDM4CGPBAR1PIP4K2ALIMK1 | |
| SCHEMBL3151005 | 0.85 | GSK3B (0.50) | KDM4CPIP4K2A | |
| SCHEMBL3151007 | 0.85 | GSK3B (0.50) | KDM4CPIP4K2A | |
| SCHEMBL2004844 | 0.84 | KDM4C (0.43) | KDM4CGPBAR1MCL1PIP4K2A | |
| SCHEMBL16628650 | 0.81 | GPBAR1 (0.47) | KDM4CGPBAR1 | |
| SCHEMBL2005702 | 0.80 | GPBAR1 (0.45) | KDM4CGPBAR1LIMK1 | |
| SCHEMBL6635011 | 0.80 | MAPT (0.51) | GPBAR1LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | claimed |
| EP-2021354-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | claimed |
| EP-1891106-A2 | NOVEL COMPOUNDS AS GLP-I AGONISTS | CADILA HEALTHCARE LTD. (IN) | 2008-02-27 | — | — | EP | claimed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
| EP-1883652-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2007017892-A2 | NOVEL COMPOUNDS AS GLP-I AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2007-02-15 | — | — | WO | claimed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | claimed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | claimed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7534763-B2 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | KDM4C 3122/4885GPBAR1 178/4885MCL1 1521/4885 |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | GLP1R, GIPR, IAPP | KDM4C 3162/4885GPBAR1 140/4885MCL1 1506/4885 |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | GLP1R, GIPR, GRPR | KDM4C 4033/4885GPBAR1 17/4885MCL1 3247/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | KDM4C 3164/4885GPBAR1 153/4885MCL1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.